Vectus Biosystems (ASX: VBS) Granted FDA Pre-IND Meeting for VB0004

Vectus Biosystems has secured a pre-Investigational New Drug Type B meeting with the US Food and Drug Administration for VB0004, giving the clinical-stage biotechnology company a formal channel for feedback on its proposed development program in idiopathic pulmonary fibrosis.

The FDA is expected to provide detailed written responses by mid-November 2026. Vectus will now work with its US regulatory agent, Cardinal Health Regulatory Services, to finalise and submit the meeting package.

For shareholders, the key outcome will be the FDA’s guidance on the clinical and regulatory work required to advance VB0004 in the US. The agency’s decision grants Vectus’ meeting request, while the written feedback will help determine the program’s next steps.

Chief executive and chief technology officer Dr Tara Speranza said: “FDA granting of our pre-IND meeting request represents an important step in progressing the US regulatory pathway for VB0004 and provides us with the opportunity to obtain formal guidance on our proposed development program in IPF.”

Lead program moves into US regulatory process

VB0004 is Vectus’ lead drug candidate and is being developed as an oral treatment for idiopathic pulmonary fibrosis, a progressive and often fatal lung disease. The compound is described as a first-in-class vasoactive intestinal peptide mimetic and natriuretic peptide receptor C agonist.

Vectus has completed a Phase Ia clinical study of VB0004 in healthy volunteers. According to the company, that study established a favourable safety and pharmacokinetic profile. The candidate has also demonstrated an ability to reverse established fibrosis in preclinical models, although that earlier finding is distinct from evidence of efficacy in patients.

The pre-IND process is intended to establish the regulatory foundation for future US clinical development. Vectus has not yet outlined a subsequent clinical trial timetable in this announcement, making the FDA’s November feedback the next defined event for the program.

VB0004 sits within a wider portfolio targeting diseases caused by pathological tissue scarring. Beyond idiopathic pulmonary fibrosis, Vectus is advancing antifibrotic assets aimed at cardiovascular, renal and liver fibrosis.

One renal fibrosis asset is already subject to a licensing agreement with an international biotechnology company. Vectus said that agreement provides a potential pathway to milestone and royalty revenue, although no financial terms were included in this update.

The immediate focus remains VB0004 and the meeting package. The FDA’s written responses should give Vectus greater clarity on what will be required before the candidate can progress further through the US clinical and regulatory pathway.